Mark Kendall (engineer)

Last updated

Mark Kendall
Born (1972-04-16) 16 April 1972 (age 51)
Nationality Australian
OccupationBiomedical engineer
Employer Australian National University
Known forBiomedical invention

Mark A. F. Kendall (BE PhD FTSE FRSA FNAI) (born 1972) is an Australian biomedical engineer, inventor, scientist and entrepreneur.

Contents

He is Founder and CEO of WearOptimo Pty Ltd [1] and the Vice-Chancellor's Entrepreneurial Professor at the Australian National University. [2]

Kendall was formerly the Professor of Biomedical Engineering at the University of Queensland, where he led a team at the Australian Institute for Bioengineering and Nanotechnology[ citation needed ]. He was Founder, CTO and a Director of Vaxxas[ citation needed ]. Prior to this, in the UK, he was a University Research Lecturer at the University of Oxford and a lecturer at Magdalen College, Oxford [ citation needed ]. Whilst at Oxford, Kendall was Associate Director of the PowderJect Research Centre for Gene and Drug Delivery[ citation needed ].

Kendall serves at the co-chair of the $150 million Australian Stem Cell Therapies Mission [3] and on the World Economic Forum Global Future Council on Biotechnology. [4]

Kendall has filed more than 160 patents (including territories)[ citation needed ], published in excess of 300 papers[ citation needed ], licensed his technologies seven times (including to Merck & Co.)[ citation needed ] and partnered globally, including with the World Health Organization, and the Bill & Melinda Gates Foundation. [5] The biotech enterprises he has founded or made significant contribution to have generated in the region of $2 billion Aus in value[ citation needed ].

Kendall's contributions to innovation in global healthcare has been recognised with more than forty awards. These include recent elections as:

• World Economic Forum Technology Pioneer (2015). [6]

• Fellow of ATSE; Australian Academy of Technological Sciences and Engineering (2017). [7]

• Fellow of the Royal Society for the encouragement of Arts, Manufacture and Commerce (now the RSA), UK; (2017)[ citation needed ].

Kendall is a CSL Young Florey Medallist [8] and Rolex Laureate. [9] [10]

Kendall's work regularly features in international media, including on the National Geographic Channel. [11]

Kendall's TedGlobal talk has been viewed more than a million times. [12]

https://www.ted.com/speakers/mark_kendall

Background

Kendall was born on 16 April 1972. [13] He received his Bachelors of Engineering (Hons I, 1993) and PhD (1998) from the University of Queensland. [14]

In 1998, Kendall moved to the UK to take up a position in the Department of Engineering Science at the University of Oxford (1998-2006). He has subsequently held positions at the University of Queensland (2006-2018)[ citation needed ] and at the Australian National University (2018–Present)[ citation needed ].

Contributions to Biotechnology

Kendall has over 160 patent applications of which[ citation needed ], 128 have been granted to date[ citation needed ]. He has authored more than 300 refereed papers[ citation needed ].

At the University of Oxford [14] (1998-2006) Kendall developed a biolistic technique for the delivery of vaccines directly into the skin without the use of needles.

At the University of Queensland (2006-2018) Kendall invented the Nanopatch [15] [16] for needle-free delivery of vaccines. [17] [18]

At WearOptimo [19] and the Australian National University [20] (2018 to present), Kendall has invented the Microwearable™ [21] [22] sensor for personalised medicine.

During his career, Kendall has collaborated with major global health partners including the Bill & Melinda Gates Foundation, [23] World Health Organization [24] [25] and Merck & Co. [26]

He is an Australian Government Academy of Science COVID-19 Expert. [27]

Selected Awards, Honours and Prizes

Contributions to biotech companies

As Associate Director of the Oxford University PowderJect Research Centre (2000-2006)[ citation needed ], Kendall advanced biolistics technology[ citation needed ], commercialised with PowderJect[ citation needed ], purchased by Chiron (later Novartis) in 2003[ citation needed ]; and then with PowderMed, purchased by Pfizer in 2006[ citation needed ].

Kendall founded Vaxxas in 2011 to advance his Nanopatch [15] technology for global impact, securing more than $40 million of investment, in the series A ($15m) [37] and B (in excess of $25m) rounds. [38] The Nanopatch technology has been licensed to Merck & Co. He served as the Vaxxas Chief Technology Officer, Director, and Chair of the Vaxxas Advisory Board (2011-2015).

In 2018, Kendall founded WearOptimo [39] where he serves as CEO.

Related Research Articles

<span class="mw-page-title-main">University of Queensland</span> University in Australia

The University of Queensland is a public research university located primarily in Brisbane, the capital city of the Australian state of Queensland. Founded in 1909 by the Queensland parliament, UQ is one of the six sandstone universities, an informal designation of the oldest university in each state. UQ is also a founding member of edX, Australia's leading Group of Eight and the international research-intensive Association of Pacific Rim Universities.

<span class="mw-page-title-main">Australian National University</span> National research university in Canberra, Australian Capital Territory

The Australian National University (ANU) is a public research university and member of the Group of Eight, located in Canberra, the capital of Australia. Its main campus in Acton encompasses seven teaching and research colleges, in addition to several national academies and institutes.

<span class="mw-page-title-main">Group of Eight (Australian universities)</span> Coalition of Australian tertiary institutions

The Group of Eight (Go8) comprises Australia's most research intensive universities - the University of Adelaide, the Australian National University, the University of Melbourne, Monash University, the University of New South Wales, the University of Queensland, the University of Sydney and the University of Western Australia. It is often compared to the Russell Group of pioneering research universities in the United Kingdom.

<span class="mw-page-title-main">Ian Frazer</span> Scottish-born Australian immunologist

Ian Hector Frazer is a Scottish-born Australian immunologist, the founding CEO and Director of Research of the Translational Research Institute (Australia). Frazer and Jian Zhou developed and patented the basic technology behind the HPV vaccine against cervical cancer at the University of Queensland. Researchers at the National Cancer Institute, Georgetown University, and University of Rochester also contributed to the further development of the cervical cancer vaccine in parallel.

The Florey Medal, also known as the CSL Florey Medal and the Florey Medal for Lifetime Achievement, is an Australian award for biomedical research named in honour of Australian Nobel Laureate Howard Florey. The medal is awarded biennially and the recipient receives $50,000 in prize money.

<span class="mw-page-title-main">Ruth Bishop</span> Australian virologist (1933–2022)

Ruth Frances Bishop was an Australian virologist, who was a leading member of the team that discovered the human rotavirus.

The Australian Institute of Policy and Science (AIPS) is an Australian non-partisan and non-profit organisation that aims to further public understanding of the public policy and science in Australia. Founded in 1932 as the Australian Institute of Political Science during the Great Depression, the organisation's initial aim was focused on economic matters. In 2006 the organisation changed its name to the AIPS to better reflect its objectives and activities. AIPS receives funding from the Australian Government and state governments, universities and the corporate sector. AIPS currently has offices in New South Wales, Victoria and South Australia.

<span class="mw-page-title-main">UQ Law School</span> Law school of the University of Queensland in Brisbane, Australia

The UQ Law School is the law school of the University of Queensland in Brisbane, Australia. Founded in 1936, the school is the sixth-oldest law school in Australia and the oldest and most prestigious in Queensland. Its alumni include six Australian High Court Justices, including two Chief Justices of Australia.

Jian Zhou was a Chinese virologist and cancer researcher, who with fellow researcher Ian Frazer, invented Gardasil and Cervarix, the vaccines for stimulating human immunological resistance to the cervical cancer-inducing human papilloma virus.

<span class="mw-page-title-main">Australian Institute for Bioengineering and Nanotechnology</span>

The University of Queensland's Australian Institute for Bioengineering and Nanotechnology (AIBN) was established in 2003. It is one of four stand-alone research institutions at the university with more than 500 researchers, students and support staff. The inaugural Director was Peter Gray. The institute's second director, Professor Alan Rowan, commenced in 2016.

<span class="mw-page-title-main">Queensland Brain Institute</span> Neuroscience research institute at the University of Queensland in Brisbane, Australia

The Queensland Brain Institute (QBI) is an Australian neuroscience research institute, located in Brisbane at the St Lucia campus of The University of Queensland (UQ). Founding director Professor Perry Bartlett established the QBI in 2003 with assistance from The University of Queensland, Queensland State Government, and Chuck Feeney, founder of The Atlantic Philanthropies. The purpose-built facility was commissioned in 2004 and on 19 November 2007, the building was opened by former Queensland Premier Anna Bligh.

Brian J. Bellhouse was a British academic, engineer, and entrepreneur, the inventor of PowderJect, a needle-free injection system for delivering medications and vaccines. He was also a professor at the University of Oxford.

Elizabeth P. Rakoczy is a Hungarian-born molecular ophthalmologist. She is a professor at the University of Western Australia. She started the molecular ophthalmology department at the Lions Eye Institute. In 2017, Rakoczy was awarded the Florey Medal for her human gene therapy trial to modify viruses for the treatment of wet age-related macular degeneration.

Lianzhou Wang is a Chinese Australian materials scientist and professor in the School of Chemical Engineering at the University of Queensland. He is director of the Nanomaterials Centre (Nanomac) and a senior group member at the Australian Institute for Bioengineering and Nanotechnology at the University of Queensland, as well as a Fellow of the Royal Society of Chemistry.

<span class="mw-page-title-main">Elanor Huntington</span> Australian computer scientist

Elanor H. Huntington is Executive Director of Digital, National Facilities & Collections at the Commonwealth Scientific and Industrial Research Organisation and a Professor of Quantum Cybernetics at the Australian National University. She led a research program in the Australian Research Council Centre of Excellence for Quantum Computation and Communication Technology.

Professor Wendy Elizabeth Hoy AO is a Fellow of the Australian Academy of Science (FAA), the Director of the Centre for Chronic Disease at the University of Queensland, Australia, and was appointed an Officer of the Order of Australia (AO) in 2010 and elected as a member of the Australian Academy of Science in 2015. Hoy's research has involved developing new types of kidney imaging and improving health and lives for indigenous populations, in Australia, Sri Lanka and the USA.

A molecular clamp is a polypeptide used to maintain the shape of proteins in some experimental vaccines. On a virus, pre-fusion proteins on their surface provide an attractive target for an immune reaction. However, if these proteins are removed or made by recombinant technology, they lose their shape and form what is called a "post-fusion form". When part of a virus, these proteins maintain their form by forming a quaternary structure with other viral proteins. The pre-fusion state of the protein is a higher energy metastable state. The extra energy is used to overcome the activation barrier of the fusion to the cell membrane. The virus protein in combination with the clamp polypeptide is called a chimeric polypeptide.

Geraldine Fitzpatrick is an Australian professor and academic researcher who serves as the head of the Human-Computer Interaction Group at TU Wien since 2009. Her research is interdisciplinary at the intersection of social and computer sciences.

<span class="mw-page-title-main">V451 vaccine</span> Terminated COVID-19 vaccine candidate

V451 was a COVID-19 vaccine candidate developed by the University of Queensland and the Australian pharmaceutical company CSL Limited. The vaccine candidate used the University of Queensland's molecular clamp technology and the MF59 adjuvant.

<span class="mw-page-title-main">ApiJect Systems</span>

ApiJect Systems Corporation is an American company founded in 2018 by Marc Koska and based in Stamford, Connecticut that produces pre-filled single use plastic injectors. ApiJect works with pharmaceutical and biotech companies to fill their injectable drug products into single-dose prefilled injectors. The company claimed to have the capacity to manufacture pre-filled COVID-19 vaccine syringes by the end of 2020.

References

  1. ↑ "Home | WearOptimo | Microwearable devices | Australia". WearOptimo / to edit. Retrieved 8 June 2020.
  2. ↑ "ANU welcomes funding for wearable medical technology". ANU. 16 May 2018. Retrieved 8 June 2020.
  3. ↑ Hunt, Greg (13 March 2019). "Australian Stem Cell Therapies Mission" . Retrieved 8 June 2020.
  4. ↑ WEF. "Future of Biotechnology". World Economic Forum. Retrieved 8 June 2020.
  5. ↑ "After 160 years, it's time to move on from the needle and syringe". www.scienceinpublic.com.au. Retrieved 8 June 2020.
  6. ↑ "Authors". World Economic Forum. Retrieved 8 June 2020.
  7. 1 2 "Mark Kendall elected as a Fellow of the Australian Academy of Technological Sciences and Engineering (ATSE)". CBNS. 17 October 2017. Retrieved 8 June 2020.
  8. ↑ Australian Institute of, Policy and Science (27 April 2020). "Young Florey Medal" . Retrieved 9 June 2020.{{cite web}}: |first= has generic name (help)
  9. ↑ "Fear of Needles? There's New Tech on the Way". National Geographic News. 14 November 2016. Retrieved 8 June 2020.
  10. ↑ "5 Times Rolex Helped to Make the World a Better Place". Time and Tide Watches. 27 September 2016. Retrieved 8 June 2020.
  11. ↑ "Fear of Needles? There's New Tech on the Way". National Geographic News. 14 November 2016. Retrieved 10 June 2020.
  12. ↑ Kendall, Mark. "Mark Kendall | Speaker | TED". www.ted.com. Retrieved 8 June 2020.
  13. ↑ "Mark Kendall: Profile". Rolex Awards for Enterprise . Retrieved 10 June 2016.
  14. 1 2 Scott, Leisa (30 November 2013). "Professor Mark Kendall, 41, biomedical engineer/inventor". The Courier-Mail . Retrieved 10 June 2016.
  15. 1 2 Council, Australian Research (5 June 2018). "Nanopatch—Revolutionising treatment of disease across the globe". www.arc.gov.au. Retrieved 10 June 2020.
  16. ↑ "UQ technology with the power to revolutionise global vaccine delivery". UniQuest. Retrieved 10 June 2020.
  17. ↑ Vidal, John (26 December 2012). "Vaccine patch offers pain-free way to stop disease in Papua New Guinea | John Vidal". The Guardian. ISSN   0261-3077 . Retrieved 10 June 2020.
  18. ↑ ""Nanopatch" Administers Vaccines Painlessly". National Geographic Society Newsroom. 26 November 2012. Retrieved 10 June 2020.
  19. ↑ "About | WearOptimo | Established by Professor Mark Kendall | Brisbane Australia". WearOptimo / to edit. Retrieved 9 June 2020.
  20. ↑ "WearOptimo and ANU: towards a healthcare future within the fourth industrial revolution". ANU. 2 October 2018. Retrieved 8 June 2020.
  21. ↑ "WearOptimo headquarters open in Brisbane". ANU. 29 March 2019. Retrieved 8 June 2020.
  22. ↑ "Our Tech | WearOptimo | Microwearable devises | Australia". WearOptimo / to edit. Retrieved 9 June 2020.
  23. ↑ "Nanopatch Delivery of DNA-Based Malaria Vaccines to Skin: Precisely Targeting the Skin Immune System for Radically Improved Vaccines | Grand Challenges". gcgh.grandchallenges.org. Retrieved 9 June 2020.
  24. ↑ "Nanopatch polio vaccine delivers". ScienceDaily. Retrieved 9 June 2020.
  25. ↑ "Nanopatch creator Mark Kendall". Science Meets Business. 24 April 2017. Retrieved 9 June 2020.
  26. ↑ Council, Australian Research (19 July 2018). "ARC Future Fellow pioneers needle-free immunisation for the world". www.arc.gov.au. Retrieved 9 June 2020.
  27. ↑ "Expert - Mark Kendall | Australian Academy of Science". www.science.org.au. Retrieved 8 June 2020.
  28. ↑ "The Future of Biotechnology". World Economic Forum. Retrieved 10 June 2020.
  29. ↑ "Professor Mark Kendall wins the 2016 CSL Young Florey Medal". CBNS. 11 November 2016. Retrieved 10 June 2020.
  30. ↑ "2016 – Professor Mark Kendall – AIPS" . Retrieved 10 June 2020.
  31. ↑ "Media Kit – 2016 CSL Young Florey Medal". www.scienceinpublic.com.au. Retrieved 10 June 2020.
  32. ↑ "Previous Medal Winners - NFMRINFMRI" . Retrieved 10 June 2020.
  33. ↑ "4 things Australia needs to know about innovation". World Economic Forum. Retrieved 10 June 2020.
  34. ↑ "Researchers: Professor Mark Kendall". Australian Institute for Bioengineering and Nanotechnology . Retrieved 10 June 2016.
  35. 1 2 Council, Australian Research (19 July 2018). "ARC Future Fellow pioneers needle-free immunisation for the world". www.arc.gov.au. Retrieved 10 June 2020.
  36. ↑ "Nanotechnology Now - Press Release: Needle-free vaccine technology a step closer to clinical trials". www.nanotech-now.com. Retrieved 10 June 2020.
  37. ↑ Queensl, The University of; Lucia, Australia Brisbane St; Gatton, QLD 4072 +61 7 3365 1111 Other Campuses: UQ; Maps, UQ Herston; Queensl, Directions © 2020 The University of. "New vaccine delivery company starts with AUD15 million investment". UQ News. Retrieved 9 June 2020.
  38. ↑ Queensl, The University of; Lucia, Australia Brisbane St; Gatton, QLD 4072 +61 7 3365 1111 Other Campuses: UQ; Maps, UQ Herston; Queensl, Directions © 2020 The University of. "Nanopatch vaccine technology company attracts $25 million". UQ News. Retrieved 8 June 2020.
  39. ↑ "Home | WearOptimo | Microwearable devices | Australia". WearOptimo / to edit. Retrieved 10 June 2020.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.